Contents

List of contributors, vii

Preface, ix

Part I: Nature of the Condition

1 Non-alcoholic fatty liver disease: Hype or harm?, 3
Stephen H. Caldwell and Curtis K. Argo

2 NAFLD: A worldwide problem, 8
Joanna K. Dowman, Geoffrey C. Farrell, and Philip Newsome

3 Is insulin resistance the principal cause of NAFLD?, 15
Ian F. Godsland, Sanjeev Mehta, Shareen Forbes, Fabian Meienberg, Michael Yee, Simon D. Taylor-Robinson, and Desmond G. Johnston

4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis, 29
Emer Fitzpatrick and Anil Dhawan

5 Non-alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis, 36
Jay H. Lefkowitch

6 Is NAFLD different in absence of metabolic syndrome?, 44
Yusuf Yilmaz

7 Occurrence of noncirrhotic HCC in NAFLD, 50
Dawn M. Torres and Stephen A. Harrison

Part II: Factors in Disease Progression

8 Fibrosis progression: Putative mechanisms and molecular pathways, 61
Wing-Kin Syn and Anna Mae Diehl

9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation?, 72
Elizabeth M. Brunt and David E. Kleiner

10 Of men and microbes: Role of the intestinal microbiome in non-alcoholic fatty liver disease, 82
Muhammad Bilal Siddiqui, Mohammed Shadid Siddiqui, and Arun J. Sanyal

11 Can genetic influence in non-alcoholic fatty liver disease be ignored?, 91
Yang-Lin Liu, Christopher P. Day, and Quentin M. Anstee

12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events?, 103
Soo Lim

Part III: Diagnosis and Scoring

13 How to best diagnose NAFLD/NASH?, 113
Vlad Ratziu

14 The clinical utility of noninvasive blood tests and elastography, 124
Emmanuel A. Tsochatzis and Massimo Pinzani

15 Are the guidelines—AASLD, IASL, EASL, and BSG—of help in the management of patients with NAFLD?, 131
Cristina Margini and Jean-François Dufour

16 Imaging methods for screening of hepatic steatosis, 138
Hero K. Hussain

17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages?, 152
Jeremy F. L. Cobbold and Simon D. Taylor-Robinson

18 Screening for NAFLD in high-risk populations, 161
Nader Lessan

Part IV: Value of Treatment Measures

19 Defining the role of metabolic physician, 173
Nicholas Finer
20 Should physicians be prescribing or patients self-medicating with orlistat, vitamin E, vitamin D, insulin sensitizers, pentoxifylline, or coffee?, 182
Haripriya Maddur and Brent A. Neuschwander-Tetri

21 Effects of treatment of NAFLD on the metabolic syndrome, 189
Hannele Yki-Järvinen

22 What are the dangers as well as the true benefits of bariatric surgery?, 196
Andrew Jenkinson

23 Liver transplantation: What can it offer?, 203
Roger Williams

Part V: What Does the Future Hold?

24 Molecular antagonists, leptin or other hormones in supplementing environmental factors?, 211
Jonathan M. Hazlehurst and Jeremy W. Tomlinson

25 What is the role of antifibrotic therapies in the current and future management of NAFLD?, 218
Natasha McDonald and Jonathan Fallowfield

26 Developmental programming of non-alcoholic fatty liver disease, 226
Jiawei Li, Paul Cordero, and Jude A. Oben

Index, 232